Oruka Therapeutics
ORKA
95.81
-1.76
-1.80%
Oruka Therapeutics
US · ORKA
#2003 by market cap
Listed 1970
95.81
-1.76
-1.80%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 7.7 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 115.02% -7.74pp
- Institutions
- 312 +3
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund71.11%
Hedge Fund25.97%
VC/PE Fund13.55%
Individual/Insider2.16%
Private Company1.78%
Public Company1.64%
Sovereign Wealth Fund0.38%
Government Pension Fund0.26%
Insurance Company0.21%
Top holders as of 2026-09-30
FMR
14.96% · 10.15M sh
BlackRock
7.68% · 5.21M sh
VR Management, LLC
6.12% · 4.15M sh
Fairmount Funds Management LLC
5.46% · 3.71M sh
Capital Research
5.06% · 3.43M sh
RTW Investments, LP
4.63% · 3.14M sh
State Street Global Advisors
4.25% · 2.82M sh
Vanguard Capital Management, LLC
3.90% · 2.64M sh
Paradigm Biocapital Advisors LP
3.16% · 2.14M sh
Franklin Resources
3.07% · 2.03M sh
T. Rowe Price Group, Inc.
2.93% · 1.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 7 buys · 43 sells
| Name | Role | Stake |
|---|---|---|
| Lawrence Klein | Chief Executive Officer | 1.36% |
| Laura Sandler | Chief Operating Officer | 0.35% |
| Larry Edwards | Chief Commercial Officer | 0.15% |
| Cameron Turtle | Former Independent Director | 0.13% |
| Carl Dambkowski | Independent Director | 0.06% |
| Joana Goncalves | Chief Medical Officer | 0.05% |
| Paul Quinlan | General Counsel | 0.04% |
| Arjun Agarwal | Senior VP of Finance & Treasurer | 0.02% |
| Bong Koh | -- | -- |
| Kristine Ball | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Kristine Ball | Independent Director | Derivative Exercise and Sale | -18,000 | $6.84–106.99 |
| 2026-11-11 | Arjun Agarwal | Senior VP of Finance & Treasurer | Derivative Exercise and Sale | -10,000 | $12.50–107.00 |
| 2026-11-01 | Lawrence Klein | Chief Executive Officer | Derivative Exercise and Sale | -25,000 | $7.80–98.40 |
| 2026-10-19 | Paul Quinlan | General Counsel | Derivative Exercise and Sale | -9,000 | $7.80–79.49 |
| 2026-10-14 | Joana Goncalves | Chief Medical Officer | Derivative Exercise and Sale | -7,000 | $6.84–77.71 |
| 2026-10-11 | Arjun Agarwal | Senior VP of Finance & Treasurer | Derivative Exercise and Sale | -9,999 | $12.50–82.84 |
| 2026-09-30 | Lawrence Klein | Chief Executive Officer | Derivative Exercise and Sale | -25,000 | $7.80–84.78 |
| 2026-09-20 | Paul Quinlan | General Counsel | Derivative Exercise and Sale | -10,000 | $7.80–95.31 |
| 2026-09-20 | Arjun Agarwal | Senior VP of Finance & Treasurer | Automatic Disposition | -533 | $95.75 |
| 2026-09-14 | Paul Quinlan | General Counsel | Open Market Disposition | -1,039 | $95.71 |
| 2026-09-14 | Joana Goncalves | Chief Medical Officer | Open Market Disposition | -947 | $95.71 |
| 2026-09-14 | Joana Goncalves | Chief Medical Officer | Derivative Exercise and Sale | -7,000 | $6.84–94.22 |
| 2026-09-14 | Lawrence Klein | Chief Executive Officer | Open Market Disposition | -2,452 | $95.71 |
| 2026-09-14 | Arjun Agarwal | Senior VP of Finance & Treasurer | Open Market Disposition | -560 | $95.71 |
| 2026-09-14 | Laura Sandler | Chief Operating Officer | Open Market Disposition | -906 | $95.71 |
| 2026-09-10 | Arjun Agarwal | Senior VP of Finance & Treasurer | Derivative Exercise and Sale | -9,459 | $12.50–94.02 |
| 2026-08-31 | Lawrence Klein | Chief Executive Officer | Derivative Exercise and Sale | -75,000 | $7.80–92.44 |
| 2026-08-31 | Laura Sandler | Chief Operating Officer | Derivative Exercise and Sale | -5,000 | $7.80–92.01 |
| 2026-08-23 | Larry Edwards | Chief Commercial Officer | Other Acquisition | +100,000 | -- |
| 2026-08-23 | Larry Edwards | Chief Commercial Officer | Other Derivative Acquisition | +20,000 | $102.42 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Oruka Therapeutics discussion 0 comments